IDH1 mutates in cholangiocarcinoma gain neomorphic enzymatic activity, whereby IDH1 is an important metabolic enzyme, and IDH1 can converts the NADPH-dependent reduction of α-KG to 2-hydroxyglutarate (2-HG) [11, 12]. This evidence concerns the gene IDH1 and cholangiocarcinoma.